tailieunhanh - Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

As the debate on the future of pain medicine unfolds, stakeholders at all levels are taking note of the exciting potential for an optimal system of pain care delivery. However, more delays in advancing the cause of pain medicine will place the United States further behind other countries, such as Australia and China, which have already recognized pain medicine as a medical specialty, and the European Union and Canada, which are also considering such a development. Therefore, in the interests of individual patients and the public at large, it is time to consolidate disparate interests in the pursuit of an. | Ichim et al. Journal of Translational Medicine 2011 9 25 http content 9 1 25 TRANSLATIONAL MEDICINE REVIEW Open Access Intravenous ascorbic acid to prevent and treat cancer-associated sepsis 3 24 2 1 1 Thomas E Ichim Boris Minev Todd Braciak Brandon Luna Ron Hunninghake Nina A Mikirova I S m ỉ I r 1 - - 1 h I I h - S 4 I r I r5 I cry o D h ỉ if s 4 s ly l r r KỈ6 l A KI I I A I r s 4 rr r i I 7 r 1 1 1 A l A s r s I 18 James A Jackson Michael J Gonzalez Jorge R Miranda-Massari Doru I Alexandrescu Constantin A Dasanu 2 9 10 2 11 12 Vladimir Bogin Janis Ancans R Brian Stevens Boris Markosian James Koropatnick Chien-Shing Chen Neil H Riordan1 2 Abstract The history of ascorbic acid AA and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation particularly progression to systemic inflammatory response syndrome SIRS and multi organ failure MOF has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in a maintaining endothelial and suppression of inflammatory markers b protection from sepsis in animal models and c direct antineoplastic effects we propose the use of ascorbate as an adjuvant to existing modalities in the treatment and prevention of cancer-associated sepsis. Personal Perspective Having worked in the area of cancer research for over a decade the major focus of one of the authors investigations has been to develop therapeutic solutions by using siRNA to directly inhibit growth of tumors 1 and to stimulate tumor immunity using antigen-specific vaccines 2-4 or unorthodox immune-modulatory approaches 5-9 . Not until the author s mother passed away from leukemia did he realize that while many